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Glucocorticosteroids play a key role in suppressing the 
inflammatory process in acute severe asthma. The choice and 
dose of a particular steroid has largely been determined 
empirically, whilst the the relative clinical efficacy of 
different types of intravenous steroids in acute severe 
asthma is not clear in published studies. 
Hydrocortisone and Methylprednisolone are the most commonly 
used agents in this setting. A wide disparity in the costs 
of these two drugs necessitated the evaluation of their 
relative efficacy. 
A randomised prospective study of Asthma Unit admissions 
over a three month period was conducted. The study design 
was guided by epidemiological principles with the purpose of 
answering the question posed at a pragmatic level. 
Therapy consisted of 4-hourly 
intravenous aminophylline and either 
hourly IVI or Methylprednisolone 
nebulised salbutamol, 
Hydrocortisone 200mg 4-
125mg 12-hourly IVI. 
Patients whose treatment differed from the basic protocol as 
well as those who required further intensification of 
therapy were analysed separately. The endpoints of the 
study were 1) the time taken to achieve maximum peak 
expiratory flow rate in hours and 2) the duration of 
hospital admission. 
386 patients were admitted to the Asthma Unit. After 
exclusions 191 patients were used in the analysis 
(Hydrocortisone n=91, Methylprednisolone n=lOO). The groups 
were comparable with respect to baseline data. The median 
time to maximum Peak Expiratory Flow Rate was 19 hours for 
Hydrocortisone and 23 hours for Methylprednisolone (median 
iii 
test, p=0,21). Median duration of Asthma Unit stay was 30 
hours for Hydrocortisone and 36 hours for Methylprednisolone 
(median test, p=0.01). A similar significant difference was 
shown when comparing patients who had been on prior oral 
maintenance steroids. In those patients with an admission 
duration greater than 48 hours, the methylprednisolone group 
had achieved a lower percentage of predicted peak expiratory 
flow rate (56.9%) compared to the hydrocortisone group 
(71.8%). This difference was statistically significant 
(p=0.009 Mann-Whitney U test). 
It was concluded that, at the dosages selected, 
Hydrocortisone is more effective than Methylprednisolone in 
acute severe asthma. Methylprednisolone has an advantage in 
that its use produces considerable saving in terms of 
nursing time and consumable expenditure (needles,swabs, 
syringes). At the time of the study methylprednisolone was 
considerably cheaper than hydrocortisone. It was therefore 
felt that practical considerations ( cost and convenience) 
should be accorded greater influence in the clinical choice 
of steroid particularly as the difference in efficacy which 
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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND: 
The pathophysiological changes in acute severe asthma 
include bronchoconstriction, mucous plugging and an 
inflammatory response in the airways. The fact that 
inflammation is a critical feature in the pathogenesis has 
been increasingly appreciated since the post mortem 
demonstration of widespread airway inflammation following 
death from asthma. 1 The suppression of this process with 
glucocorticosteroids has become standard practice since the 
MRC trial in 1956 2 and many subsequent studies.
3 , 4 , 5 
Glucocorticosteroids exert their anti-inflammatory action by 
modulation of several cellular and biochemical pathways 
6 
which are not completely understood. In the setting of 
acute severe asthma, hydrocortisone (HC) and 
methylprednisolone (MP) are the most commonly used 
glucocorticosteroids. The administration of these 
glucocorticosteroids in equivalent biopotent doses produces 
equivalent anti-inflammatory activity and it is often 
assumed that their relative clinical efficacy is similarly 
equal. The comparison of these corticosteroids has not 
formed part of any previously published large clinical 
study. 
1.2 OBJECTIVES OF THE STUDY: 
This study aimed to examine the relative clinical efficacy 
of HC and MP in acute severe asthma. An important part of 
the study was to conduct the investigation as part of the 
normal functioning of the Asthma Unit and to compare the two 
steroids using the doses and dose-intervals in common 
clinical use at Groote Schuur Hospital. In view of 
2 
increasing financial constraints, the need to determine the 
most cost-effective therapy has become a priority in this 
institution. 
1.3 OBJECTIVES OF THE DISSERTATION: 
The dissertation aims to i) place this clinical research in 
perspective with regard to previous work in this field, ii) 
justify the research methods and iii) review the results and 
issues arising from them. 
1.4 METHODS: 
The study was an open prospective parallel randomised trial 
of HC 200mg 4-hourly IVI vs MP 125mg 12-hourly !VI in acute 
severe asthma. All Asthma Unit admissions over a 3 month 
period were eligible for the study. Data was collected on 
all asthmatic admissions to the hospital during the study 
period. (The methods employed in this study are described 
in detail in Chapter 6.) 
1.5 LIMITATIONS AND CONSTRAINTS: 
The study received no support in the form of grants, drugs 
or equipment from any external source. 
1.6 CHAPTER OUTLINE: 
The second chapter of this work defines the clinical 
research problem and outlines the background which prompted 
this research. Chapter 3 examines glucocorticosteroids and 
the theoretical basis for their efficacy in asthma as anti-
inflammatory agents. Previous clinical studies of the 
efficacy of glucocorticoids in acute severe asthma are 
3 
reviewed in Chapter 4 with special reference to their 
statistical power and steroid dosage. The following chapter 
outlines i) the basic principles of research methodology as 
applicable to this study, ii) the relevance of the chosen 
study design and iii) problems in clinical studies of acute 
severe asthma. The methods of the study ( described as an 
interventional survey) are described in Chapter 6. The 
results of the study and their statistical analysis are 
presented in Chapter 7. A discussion of the results follows 
in Chapter 8, where the issues of drug costs and cost-
efficacy are raised. Finally, conclusions based on the 
results are drawn and recommendations are made. 
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CHAPTER 2: THE CLINICAL RESEARCH PROBLEM 
The use of glucocorticosteroids in acute severe asthma is 
accepted clinical practice. However the choice of 
corticosteroid as well as the specific doses and dose 
intervals are still controversial. 
The two glucocorticosteroids examined in this study are 
those in most common clinical use at Groote Schuur Hospital. 
There is disagreement amongst clinicians as to which drug is 
more effective. In addition there is a wide disparity in 
the cost of the two drugs. The need to rationalise 
escalating drug expenditure prompted this study to determine 
which agent was more effective as well as cost-effective. 
The clinical research problem was therefore primarily to 
examine their relative clinical efficacy. Furthermore the 
study would have to demonstrate the difference ( if any) 
based on a population sample which is representative of the 
majority of acute severe asthmatics seen at Groote Schuur 
Hospital. 
As far as implementation of the study was concerned, a prime 
objective was that it be conducted in the course of the 
ordinary functioning of the Asthma Unit without the 
unrealistic influences which a strict protocol-driven 
experimental design would impose. In order to satisfy these 
objectives a large sample population was necessary. An 
observational or epidemiological method of study was 
therefore adopted. By adhering closely to the principles of 
experimental study design (with randomisation and a clearly 
defined management protocol), the use of the observational 
method might still be possible in this situation and thus 
could be termed an interventional survey. 
5 
The hypothesis on which the research was based was that (on 
the grounds of biologic equipotency at the chosen dosages) 
both corticosteroids were equally effective. However it was 
anticipated that, although similarly effective, practical 
considerations of cost and convenience might favour MP. At 
issue, therefore, was whether cost considerations may be 
pre-eminent; for, while MP requires much less nursing time 
to administer as a 12-hourly regimen (BC was given 4-
hourly), this advantage would only be clinically relevant if 
overall hospital stay was similar for both agents (or 
favoured MP). 
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CHAPTER 3: GLUCOCORTICOSTEROIDS AND ACUTE SEVERE ASTHMA 
3.1 STRUCTURE: 
Glucocorticosteroids are composed of a 
cyclopentenophenathrene ring with varying side groups to 
form a 21 carbon molecule (Figure 1) 7 • Hydrocortisone has a 
double bond between C4 and CS, ketone groups at C3 and C20, 
and hydroxyl groups at Cll, C17 and C21. In 
methylprednisolone there is a double bond between Cl and C2 
(increasing anti-inflammatory and decreasing 
mineralocorticoid action) and an additional methyl group at 
CG.a 
3.2 PHARMACOKINETICS AND PHARMACODYNAMICS: 
Following absorption and distribution, factors which affect 
the availibility of free steroid include the extent of 
binding to plasma proteins, the rate of degradation and the 
steroid's affinity for intracellular receptors. In the case 
of cortisol 75% is bound to transcortin and 15% to albumin.
9 
When the cortisol concentration is increased it eventually 
saturates this protein binding and the quantity of free 
(active) steroid is greatly increased. Structural 
differences in steroid analogues interfere with protein 
binding and thus increase the fraction of steroid which is 
metabolically active.a 
Variations in the structure of different glucocorticoids, as 
well as differences in absorption, distribution, steroid 
receptor binding and elimination influence the magnitude and 
duration of their effects.lo 
Cortisol is inactivated in the liver by reduction to acidic 
compounds and then conjugation with glucuronic acid. The 
latter step imparts water solubility and allows renal 
Figure 1: Chemical Structure of HC and MP: 
(from British Pharmacopoeia (7)) 
HO 
Hydrocort1sone: C H O 























elimination. The metabolism ( or rate of excretion) of 
corticosteroids is increased by hyperthyroidism, 
diphenylhydantoin, adrenaline, primidone, oestrogens and 
rifampicin. 8 In contrast to this, metabolism or excretion 
is decreased by hypothyroidism, hepatic cirrhosis, renal 
disease and, in the case of MP, erythromycin and 
troleandromycin. 8 The relative plasma half-lives and 
potency of HC and MP are illustrated in Table I (from Dunlap 
and Fulmer8 ). 
TABLE 3.1: RELATIVE POTENCY AND HALF-LIVES OF 
















Schwartz et al found that plasma clearance of HC was 
increased in patients requiring greater than 15mg of 
prednisone a day in order to maintain asthmatic control.
11 
These patients also had a diminished eosinopaenic response 
to cortisol at 4 and 6 hours after the the study dose. 
Dwyer et al reported increased clearance of HC in some 
steroid treated asthmatics. 12 Absorptive differences, 
however, may be as important as those in elimination rate in 
determining peak plasma levels. Subsequent studies have 
shown no differences in the pharmacokinetics of prednisolone 
in normal and asthmatic subjects including patients who have 
received prolonged corticosteroid therapy. 1
3 , 14 
Schenfield15 found that three weeks of prednisone therapy in 
asthmatics had no effect on the plasma half-life of BC 
al though there was considerable variation in peak plasma 
levels within and between patients. Because of the 
9 
interpatient variability in plasma levels of cortisol 
achieved following intravenous HC, high doses were advised 
in order to consistently achieve the plasma levels 
recomended by Dwyer. Schenfield's findings are in agreement 
with those of Wilson et al14 , who found considerable inter-
patient variation in bioavailibili ty after a standard dose 
of prednisolone. 
The conflicting findings of earlier studies and the large 
corticosteroid doses reported to be required by some 
asthmatics may be partly explained by differences in the 
patients studied, prior steroid dosages, duration of steroid 
therapy and differing steroid receptor sensitivity. 
Furthermore the possible simultaneous use of other drugs 
(particularly barbiturates) may have had significant effects 
on steroid metabolism. An additional important confounder 
in all studies of acute asthma is the duration of the attack 
(which influences the degree of inflammation and mucous 
plugging). 
Response to glucocorticosteriods has been studied in animal 
models to evaluate the effect of different dosing 
strategies. In an animal model developed by Boudinot et 
a1 10 , a tenfold increase in the dose of prednisolone did not 
produce a proportional increase in effect (with hepatic 
tyrosine aminotransferase used as a marker). The maxJ.mum 
response increased by 50% and the duration of response was 
only doubled. In a subsequent study it was observed that 
smaller doses administered more frequently are much more 
effective than large single doses. 16
 Reiss et a1 17 examined 
a single (40mg) dose methylprednisolone regimen and compared 
this to a split dose regimen by measuring the effect on 
blood histamine and plasma cortisol. Their results indicate 
that the duration of effect can be more successfully 
extended by use of a smaller total dose in a divided manner. 
10 
3.3 INFLAMMATION IN ASTHMA: 
Airway inflammation is now regarded as an integral part of 
asthma. Post mortem studies 18 , 1 of patients who died during 
status asthmaticus have described the inflammatory changes 
of oedema and an inflammatory cell infiltrate in the airway 
wall {eosinophils, neutrophils, plasma cells and 
lymphocytes ) . Furthermore there is epithelial damage and 
sloughing, basement membrane thickening and hyperplasia of 
goblet and smooth muscle cells. 
The inflammatory cells release mediators that cause airway 
hyperresponsiveness. After allergen exposure in a sensitive 
patient there is a release of mediators primarily of mast 
cell origin resulting in immediate bronchoconstriction and 
increased airway secretions (early phase response). 
Additional mediator release and sustained 
bronchoconstriction with the recruitment of eosinophils and 
neutrophils follows several hours after significant allergen 
exposure ( late phase response) • These events result in 
damage to the epithelial lining and exposure of receptors to 
irritant stimuli. A detailed discussion of the 
inflammatory-cell biology in the pathophysiology of asthma 
is beyond the scope of this dissertation. The role of 
mediators such as histamine, eicosanoids and cytokines and 
the associated cellular events in this process are reviewed 
by McFadden and Gilbert. 19 Despite the incomplete 
understanding of the cellular and biochemical mechanisms 
highlighted in this review, there is ample evidence of an 
inflammatory process in the airways of patients with asthma. 
As a result of this new understanding, the primary goal of 
therapy is increasingly directed towards resolving 
inflammation. Glucocorticosteroids are the most potent 
agents available for this purpose. 
11 
3.4 MECHANISM OF GLUCOCORTICOSTEROID ACTION: 
Mechanisms of action which have been proposed for 
glucocorticosteroids in asthma include their effect on 
leukocyte traffic and function, altered chemotaxis, impaired 
mediator synthesis and release, enhanced beta-adrenergic 
receptor activity and decreased vascular permeability.
20,21 
According to the general model of steroid hormone action, 
steroid hormones bind to cytoplasmic receptors. 
6 The 
receptor-hormone complex is then translocated to the nucleus 
where the synthesis of specific mRNA is induced. The 
effects of the steroid are only seen after the subsequent 
protein synthesis. The nature of the response in the 
affected cell is determined by its state of differentiation 
and further modulated by its metabolic and hormonal state.2
2 
A further point is that the duration of action of the 
steroid will vary according to the half-life of the induced 
protein. 
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CHAPTER 4: CLINICAL STUDIES OF GLUCOCORTICOSTEROIDS IN ACUTE 
SEVERE ASTHMA. 
4.1 INTRODUCTION: 
In 1956 the MRC trial 2 showed that oral cortisone acetate 
produced superior improvement compared to placebo in 
patients with status asthmaticus who had been unresponsive 
to 24 hours of conventional therapy. Subsequent studies 
have demonstrated that glucocorticsteroids hasten the 
improvement in lung function and facilitate recovery from 
hypoxaemia. 
Although corticosteroids are used in the management of acute 
severe asthma, their optimal dose and duration of therapy 
are not clear from published studies. 
4.2 EVIDENCE OF CORTICOSTEROID EFFICACY: 
4.2.1 TYPE II ERROR IN PREVIOUS STUDIES: 
Numerous studies are frequently cited in support of a 
particular corticosteroid and its dosage although many of 
the studies lack the statistical power necessary for such a 
claim to be valid. The importance of the type 2 error in 
clinical trials in acute severe asthma has been examined by 
Ward. 23 In the trials which were examined3 , 4 ,s,
24 comparing 
corticosteroids with placebo, all had a probability of less 
than 60% of detecting 25% more bronchodilation in those 
treated with corticosteroids. The study by Fantas was the 
only one of these which showed a statistically significant 
difference between corticosteroids and placebo. Al though 
this study did not have a greater power, the large 
difference in response resulted in its significance. 
13 
Fanta's careful study5 of refractory asthmatics showed that 
corticosteroids speed the recovery from airflow obstruction. 
Twenty patients with acute severe asthma of comparable 
severity refractory to a combination of sympathomimetics, 
methylxanthines and B2-stimulants were randomised in a 
double blind fashion to receive placebo or BC {2mg/kg bolus 
and then O.Smg/kg/hr). During the 24 hour follow up period, 
there was no response at six hours but a significant 
difference favouring the steroid was evident at 12 hours and 
continued until the end of the study. The method used in 
the study excluded those likely to respond to bronchodilator 
therapy without the use of corticosteroids and the results 
demonstrate the efficacy of a dose of BC in the region of 
lOOOmg/24 hours. 
Pierson et al 3 found that Pa02 improved in children with 
acute asthma treated with corticosteroids but there was no 




potential for bias in this study as a result 
breaking of blinding and reassignment of 
the control to the study group. 
McFadden et al4 showed no advantage in using up to 1000mg of 
BC when compared to placebo. However when the period of 
observation was extended beyond 6 hours 
noted. 5 
4.2.2 OTHER EVIDENCE OF EFFICACY: 
a difference was 
Other good evidence for the efficacy of corticosteroids in 
acute severe asthma comes from the two following randomised 
placebo-controlled trials: the study by Fiel et a12
5 showed 
that MP administered in the emergency unit decreased the 
need for repeat emergency unit care. These findings are 
supported by those of Littenburg and Gluck
26 who showed a 
60% decrease in the admission rate of patients with acute 
severe asthma (FEV1 <50% of predicted) presenting to the 
14 
emergency unit and treated inter alia with a single 
intravenous dose of MP (125mg). 













corticosteroid treated patients when compared to controls. 
Luksza compared the PEFR in 60 patients with acute severe 
asthma treated with or without low-dose corticosteroids (HC 
400mg daily) with 30 patients treated with high dose 
steroids (HC 1200mg daily). They found no significant 
difference in the rapidity of relief of airflow obstruction 
using the higher dose compared to low dose or no steroids. 
The study interpretation is complicated by the possible 
presence of coexistent diseases and the lack of 
randomisation. A disturbingly high proportion of the cases 
required mechanical ventilation ( 13/90). The findings of 
this study have never been repeated in a comparable group of 
asthmatics. 
Morell et a129 studied 82 patients with acute severe asthma. 
This randomised double-blind trial divided the patients into 
three groups who received intravenous MP every 4 hours at 
doses of lOmg/kg or 2mg/kg or placebo. There were no 
significant differences in the baseline status of the three 
groups nor in their rates of recovery. One cannot conclude 
however, on the basis of their results, that corticosteroids 
are ineffective. The wide scatter in PEFR values may have 
obscured the results and the authors make no statement 
regarding the power of the study. In those patients who had 
failed to respond by the third hour of treatment, and in 
those who were previously taking oral corticosteroids, a 
favourable effect was seen in the high dose steroid group. 
Although this was not statistically significant, this does 
not necessarily exclude a clinically important difference. 
4.3 CORTICOSTEROID DOSE: 
4.3.1 GENERAL: 
The wide variation l.n 
glucocorticosteroids results 
controlled studies of dosage. 
studies are impossible to 
15 
recommended doses of 
from the relatively few 
In addition many of these 
interpret because of poor 
definition of patient populations, presence of pulmonary 
infections or inadequate indices of response. 
4.3.2 DWYER HYPOTHESIS: 
Dwyer12 first suggested the need to achieve levels of plasma 
cortisol >lOOug/lOOml to alleviate severe attacks of asthma. 
This group found that, following the intravenous 
administration of 100mg HC, the steroid dependent asthmatics 
had lower plasma cortisol levels compared to those never on 
steroids. Their suggestion that high plasma levels are 
necessary was, in part, based on the need to increase the 
unbound (active) plasma cortisol fraction and thus increase 
the biologic activity of administered corticosteroids. The 
validity of conclusions drawn in this study remain in doubt 




of objective criteria for severity of asthma or 
to therapy. In addition no information was 
to indicate the interval between steroid 
administration and clinical response. 
In order to achieve the levels recommended by Dwyer and 
avoid a progressive rise in serum cortisol levels a dose of 
3mg/kg HC every six hours has been recommended.
30 
Collins et a1 30 used a dose of HC between about 1000mg and 
1750mg per 24 hours and achieved plasma levels in excess of 
lOOug/dl. Plasma cortisol levels were no different between 
those asthmatics who had and those who had not received 
previous corticosteroid therapy. 
16 
Fanta et al5 found no significant correlation between plasma 
cortisol levels and improvement in lung function. 
Thus al though the Dwyer hypothesis is theoretically 
attractive, its validity has not been confirmed. 
4.3.3 DOSE COMPARISON STUDIES: 
Previous comparisons of "low" vs. "high" dose 
corticosteroids for acute asthma have failed to show any 
advantage in the use of high doses. 4 ,28, 3 l,32 
A study by Britton et al 33 compared low, medium and high 
dose corticosteroids (the equivalent of HC 280mg, 840mg and 
3500mg per 24 hours respectively). Their use of three 
different steroids via two different routes makes detailed 
comparison difficult. Furthermore their medium dose group 
was initially worse with a significantly lower mean Pa02. 
Nevertheless their study could show no advantage over the 
medium dose in the use of a very high dose of HC (equivalent 
to >3g/24 hours). 
A double blind study of intravenous MP by Tanaka et al 
32 
(comparing the equivalent of 400mg HC with 2500mg HC per 24 
hours over a seven day period) showed no significant 
difference in the pattern or magnitude of spirometric 
response. This study is, however, also impaired by the use 
of a small sample of 10 patients where the two groups were 
poorly matched (with the low dose group having a 25% higher 
baseline FEV 1) • 
In an attempt to determine the optimum dose of 
corticosteroids, Haskell et al 24 studied a small group of 
adults with acute severe asthma (FEV1 <30% of predicted). 
Patients were blindly randomised to receive intravenous MP 
every 6 hours for 3 days at doses of 15, 40 or 125mg (low, 
medium and high dose) and response in FEV1 was measured. 
The low dose group failed to improve during the 3 days of 
17 
the study. The high dose group improved significantly by 
the end of the first day and the medium dose group improved 
by the middle of the second day. This suggests that a MP 
dose of 15mg 6-hourly is inadequate al though the minimum 
dose for a response and the ceiling of the dose-respnse 
curve are unknown. No other studies have suggested that a 
dose-response relationship exists. 
The effectiveness of low doses of corticosteroids has 
recently been reported by Bowler et al.
34 In a double blind 
comparison of HC 50mg, 100mg and 500mg intravenously every 6 
hours for 48 hours they could find no difference in efficacy 
between the doses. Once again this study dealt with small 
numbers (n=66) and a type II error could not be excluded. 
In addition the duration of the attack of acute severe 
asthma was longer in the low dose group. These patients may 
therefore have been in the recovery phase of their illness, 
thereby obscuring any difference in treatment effect. Six 
hours after admission these patients had PEFRs of 60-70% of 
predicted and there was a more than twofold increase in FEV1 
in the first 24 hours. This suggests the existence of the 
confounding effect of rapidly reversing airflow limitation 
in some subjects. 
4.4 PREVIOUS COMPARISON OF HYDROCORTISONE AND 
METHYLPREDNISOLONE: 
In the only previous study of the relative efficacy of HC 
and MP in acute severe asthma, Sue et al 
35 concluded that 
there were no clinical or statistically significant 
differences in the short term airway responses of patients 
treated with equivalent doses of corticosteroids. A group 
of 14 adult males was given either HC 100mg, MP 20mg or 
dexamethasone 3. 75mg intravenously 6-hourly for 72 hours. 
At 12 as well as at 18 hours the MP group showed an 
unexplained transient deterioration. The difference in 
mean percentage of predicted FEV1 favouring HC over MP was 
18 
significant at 18 hours (p<0.05) but not at other times (12 
and 24 hours) • In the light of previously cited studies 
showing the efficacy of higher doses of steroid, the doses 
used may have been too low to demonstrate a 
glucocorticosteroid effect. 
The authors concluded that the steroids were equally 
effective while acknowledging that there was a large margin 
for type 2 error in relation to the sample size. They felt 
that a clinically significant difference was unlikely to 
become apparent in a larger study. However the question was 
raised of possible cost saving ( assuming equivalent 
efficacy) by less frequent dosing of longer-acting 
corticosteroids such as MP. 
4.5 META-ANALYSIS OF PREVIOUS STUDIES: 
A recent meta-analysis36 of 30 randomised controlled trials 
in acute severe asthma confirmed that the early use of 
corticosteroids in the emergency room reduces admissions to 
hospital in both adults and children. The data also 
indicated that oral steroid treatment in patients discharged 
from an emergency department significantly reduced the 
relapse rate at 7 to 10 days following treatment. With a 
baseline relapse risk of 20%, six patients would need to be 
treated to prevent one relapse. If the baseline admission 
risk is 20%, eleven adults would need to be treated to 
prevent one admission. It is only in the situation of a 
very low baseline risk of each complication (<=5%) that not 
using steroids could be justified. 
In the analysis of data on high dose (equivalent to >1200mg 
HC/24 hours) vs moderate (620-1200mg/24 hours) or low dose 
(200-600mg/24 hours), there was a tendency to an advantage 
over placebo in only the moderate and high dose groups. 
Al though the optimal dose could not be determined, it was 
19 
suggested that doses of less than 600mg HC/24 hours are 
suboptimal. 
In the examination of the time course of improvement in 
pulmonary function in the studies comparing intravenous 
steroid and placebo, there was a significant difference 
between individual study results (heterogeneity) at 12 and 
24 hours. A moderate "effect size" ( 0. 34) was present in 
the paediatric group at 24 hours. The "effect size" on 
pulmonary function at 36 hours was small (0.2) without 
significant heterogeneity. The heterogeneity, when present, 
could not be explained on the basis of differences in the 
study populations or study design. The authors proposed 
that because of both a lack of sensitivity and within 
patient variability of pulmonary function tests, small but 
important changes were not detected. In the light of this, 
the need for studies to be large (as pointed out by Ward 
23 ) 
remains important and is not satisfied by most of the 
published work in this field. 
4.6 SUMMARY: 
Corticosteroids are clinically useful especially in patients 
not responding to bronchodilators. Their use in acute 
severe asthma is now standard practice. 
Glucocorticosteroids have been shown to decrease morbidity, 
hospitalisation and the need for repeat emergency room care. 
The choice of specific steroid has, however, been largely 
determined empirically. The optimum steroid dosage remains 
undetermined. There appears to be no advantage in using 
very high-dose ( equivalent to HC >3g/24 hours) over lower 
dose corticosteroid (equivalent to HC ±l.2g/24 hours). 
However low doses in the region of 300mg HC/24 hours have 
not consistently been shown to be effective. The use of the 
equivalent of 1200mg HC/24 hours in this study may be 
regarded as appropriate in the light of these published 
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studies. In addition, a clinically important treatment 
effect is unlikely to be missed because of under-dosing. 
MP has several theoretical advantages over HC which include: 
greater anti-inflammatory potency, longer duration of action 
and less sodium retaining properties than a bioequivalent 
dose of hydrocortisone. 
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CHAPTER 5: CLINICAL STUDY DESIGN IN ACUTE SEVERE ASTHMA 
5.1 INTRODUCTION: 
The following discussion serves as an outline of the 
principles which guided the design of this study in line 
with the study objectives (Chapter 1) and the clinical 
research problem ( Chapter 2 ) . Some of the particular 
problems in the study of acute severe asthma are addressed. 
The design and interpretation of clinical studies in this 
situation presents several problems. Major aspects are the 
varying degrees of severity and rates of deterioration as 
well as causes of the acute attack; each of these is 
expected to influence the rate of recovery. The inherent 
variability of asthmatic airflow limitation leads to 
difficulties in assessing response to treatment.
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5.2 STUDY DESIGN: 
5.2.1 EXPERIMENTAL AND OBSERVATIONAL STUDIES: 
In the field of comparative impact research being considered 
here, the basic study design may be broadly divided into 
those with purely experimental and those with observational 
approaches. 
In experimental studies the intervention is under the 
control of the researcher with the aim being to determine 
how outcome is affected by changes in the independent 
variable. In contrast to this the researcher does not 
control the intervention in observational studies, but 
rather observes the effects of an experiment "in nature". 
The key element which distinguishes experimental from 
observational studies is randomisation. A major advantage 
of the former type of study is that (with an adequate sample 
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size) groups are more likely to be comparable because most 
extraneous variables should be balanced. 
However, since experimental studies often take place in an 
artificial setting and amongst a selected sample, the study 
population may differ from the target population with regard 
to important characteristics. If the effects of treatment 
depend on these characteristics, the observed effect in the 
study population could differ from the effect that exists in 
the target population. A potential advantage of 
observational studies is that they are often carried out in 
a setting in which the study population is more 
representative of the target population. Neither form of 
study is uniformly superior in every situation. The study 
should preferably be judged by how it meets specific 
objectives and constraints. 
In experimental and observational studies the underlying 
philosophy is the same. That is to say a group of patients 
is taken in a baseline state, subjected to an intervention 
or manoeuvre and the impact in terms of outcome is recorded. 
Although the underlying intellectual reasoning is the same, 
in epidemiologic research differences from traditional 
scientific research arise in the conduct of the research 
activity as a result of pragmatic, logistic and other 
constraints. These similarities and contrasts are described 
in detail by Feinstein38 in his book on the architecture of 
clinical research. 
5.2.2 SAMPLING, VALIDITY AND STUDY COST-EFFECTIVENESS: 
The method of sampling study subjects is important if one 
would like to generalise the findings in the sample 
population to the target population. An accepted method 
would be by random sampling. The alternative 
epidemiological method would be to sample the entire target 
population ( eg all Asthma Unit admissions), provided that 
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significant numbers of the target population were not missed 
by being treated elsewhere. Some degree of precision may be 
lost by such total target population sampling, but the 
validity of findings is probably of greater importance. In 
other words the study should provide an approximate answer 
to the correct question rather than a precise answer to the 
wrong question. Precision can then be enhanced by 
stratification (eg by degree of airflow 
obstruction/reversibility) at the analysis stage. 
Subsequent generalisation to the entire target (sampled) 
population may then be possible. 
The randomised controlled trial remains the gold standard of 
clinical research but is not the sole acceptable method. 
The quality of observational studies can be improved by 
regarding the randomised controlled trial as a model to 
guide study design at an intellectual level rather than as a 
prescribed practical method of investigation. Gray-Donald 
and Kramer39 suggested that in order to enhance validity one 
should follow as closely as possible the methods of good 
experimentation and test the scientific hypothesis in as 
many different ways as possible. By decreasing measurement 
error, avoiding sources of bias and using tools such as 
inclusion and exclusion criteria, one may obtain a result 
which approximates that obtained by a purely experimental 
study. Caution should, however be exercised if numbers are 
small and if the results are not striking. 
Inevitably a trade-off occurs between the perfect study 
design 
sought 
and its practical implementation. A balance is 
between the total value of derived information 
relative to actual expenditure. In the final choice of study 
design an attempt is made to gather the most accurate 
information for a given cost (time, money or personnel). 
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5.2.3 CONFLICTS IN DESIGN AND ANALYSIS: 
There are two basic policies (both of which are reasonable 
and justifiable) which are used in the design and analysis 
of clinical studies. Depending on the question being asked 
and the answers which are sought, one or other of these 
approaches may be pref erred. The approaches that emerge 
often lead to conflict between supporters of each policy. 
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The primary goal of a trial is usually obvious and 
demonstrates the outcome of an intervention in the groups 
under comparison. The 





standards to be used in interpreting results. 
however, 
and the 
A difference in the philosophic approach to these two 
objectives gives rise to two divergent policies. 
Feinstein 38 calls these pragmatic and fastidious policies. 
In his pragmatic approach "a trial is intended to ask 
questions and obtain answers that are directly pertinent for 
decisions in clinical practice." In contrast to this, the 
fastidious approach requires that a trial be an explicitly 
scientific activity. A single study is seldom able to 
placate both viewpoints. 
5.3 MONITORING OF RESPONSE: 
The pulmonary function test used to monitor reversal of 
airflow limitation should be both sensitive and simple to 
perform. PEFR measurement has the advantage that it can be 
used in a wide spectrum of patients from all but the most 
severe to those in a stable state. A drawback of the PEFR 
is that it is effort-dependent. The pattern of response 
with serial PEFRs is clinically useful especially where a 
large decrease in airflow limitation with repeated testing 
is seen (as in acute severe asthma), and may outweigh this 
disadvantage. The final choice of test for monitoring is an 
exercise in compromise and it is doubtful whether additional 
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measures of pulmonary function would be of added benefit in 
the type of study described here. 
5.4 DEFINITION OF OBSTRUCTION AND REVERSIBILITY: 
There is no consensus in the literature on the definition of 
obstruction nor on 
bronchodilator studies. 
what represents reversibility in 
Eliasson and De Graff examined how 
criteria employed for obstruction and reversibility, used to 
define patient populations, result in a variation of 
results. 40 They found that the outcome of a bronchodilator 
trial is affected by the degree of airflow obstruction of 
patients enrolled. Because of the effect of regression 
towards the mean, the lower the initial pulmonary function, 
the greater is the likelihood that a subsequent measurement 
will show improvement { independently of any drug effect) • 
As a result of this, as well as a minimal negative 
correlation of response with spirometry values, the most 
obstructed groups will show the greatest bronchodilator 
response. These effects are exaggerated when change in FEV1 
is calculated as a percentage of the initial value. The use 
of absolute values or the calculation of response as a 
percentage of predicted are probably more appropriate 
expressions of reversibility. 
Eliassen and De Graff also point out the large overlap in 
bronchodilator response between diseases defined by the 
terms "reversible" and "irreversible" airflow 
obstruction. 40 A group of patients labelled as having 
asthma defined in terms of bronchodilator response, is 
likely to be heterogenous and may include patients with 
chronic obstructive lung disease. 
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CHAPTER 6: PATIENTS AND METHODS 
6.1 STUDY DESIGN: 
This study was designed as an interventional survey in order 
to answer the research question at a pragmatic level. That 
is to say, an intervention was performed (randomisation 
between HC and MP) in a semi-experimental fashion; outcome 
was then reviewed using an observational method. The study 
was "epidemiological" in the sense that no attempt was made 
prospectively to match individual cases in one study limb 
with those in the other. This ensured the recruitment of 
the maximum number of patients over a three month period. 
The primary objective here was to examine the relative 
clinical efficacy of HC and MP. The secondary objective was 
to examine the issue of relative cost-effectiveness. 
6.2 STUDY POPULATION: 
All patients admitted to the Asthma Unit of Groote Schuur 
Hospital were studied over a three month period commencing 1 
November 1989. This Asthma Unit forms part of the Emergency 
Unit and during 1989 had a total of 2067 admissions. 
6.3 ROUTINE THERAPY: 
All patients who present to Groote Schuur Hospital's 
Emergency Unit with acute severe asthma and who fail to show 
a satisfactory clinical response to nebulised B2-stimulants 
and intravenous aminophylline within two hours are routinely 
admitted to the Asthma Unit. All cases receive 4-hourly 
nebulised salbutamol and intravenous aminophylline. The 
dose of aminophylline is based on estimated lean body mass 
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and adjusted when serum theophylline levels become available 
as described in the unit operating protocol in Appendix I. 
Asthmatics whose conditions are complicated by other medical 
illnesses and those needing intensive care are admitted 
elsewhere in the hospital. 
Except in the mildest cases, intravenous steroids were 
routinely administered; the trial required that either 
hydrocortisone (200mg 4-hourly IVI) or the equivalent dose 
of methylprednisolone ( 125mg 12-hourly IVI) be used. The 
criteria for the initiation of steroid therapy are indicated 
in Table 6.1. The first dose of steroid was almost always 
given within an hour of presentation to the emergency unit. 
In those cases not responding to this therapy, a salbutamol 
infusion could be added. Decisions to intensify therapy 
(eg. by adding a salbutamol infusion), to discharge patients 
or to admit a patient to an Intensive care Unit or general 
medical ward were taken by Emergency Unit staff (guided by 




CRITERIA FOR THE INITIATION OF STEROID THERAPY 
1. All patients who received corticosteroids in the 
preceding three months as part of their maintenance 
asthma treatment. 
2. All patients admitted to the Asthma Unit during 
the preceding 4 weeks. 
3. Failure to show a satisfactory response* within 1 
hour to nebulised salbutamol and intravenous 
aminophylline. 
4. All patients who on a previous admission to the 
Asthma Unit showed a slow recovery curve and/or 
required intravenous steroids. 
* Satisfactory response defined as: An improvement 
with regard to general state of distress, reduction of 
tachycardia and pulsus paradoxus and improvement of 
PEFR by 50% or more. 
6.4 RANDOMISATION: 
The steroid available for use in the Asthma Unit was 
alternated on a weekly basis throughout the study period. 
Changeover took place at 07h00 every Monday. Patients 
continued to receive the steroid given on admisson for the 
duration of their hospital stay or until converted to oral 
prednisone. 
6.5 MANAGEMENT PROTOCOL: 
During the trial period the criteria for (i) admisson to the 
Asthma Unit, (ii) therapy with bronchodilators and/or 
steroids, (iii) referral to the Intensive Care Unit and (iv) 
discharge from hospital were not different to those in place 
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for the preceding seven years. The specific discharge 
criteria are described in Table 6.2. 
TABLE 6. 2: 
DISCHARGE CRITERIA 
ALL 3 CRITERIA TO BE FULFILLED 
1. No features of distress and able to walk to the 
toilet. 
2. PEFR showing an upward trend and/or plateaued at 
more than 70% of the patient's best PEFR in the past 
year (or, if not available, predicted normal PEFR) AND 
morning dipping is not below 50% of the patient's best 
PEFR in the past year (or predicted normal PEFR) 
3. Patient feels that he/ she would be able to cope 
at home. 
6.6 MONITORING: 
As a result of the issues raised in paragraph 5.3, patients 
were monitored, as usual, by charting 4-hourly PEFR 
measurements. Daily serum theophylline levels were 
performed. The same Wright's mini peak flow meter was used 
on all patients and was checked daily on a non-asthmatic 
control. Serum electrolytes, urea and creatinine, arterial 
blood gases, chest X-ray and sputum cultures were performed 
when indicated on clinical grounds. 
6.7 ENDPOINTS: 
Two primary endpoints were used, these being ( i) the time 
taken to achieve maximum PEFR ( in hours ) and ( ii) the 
duration of Asthma Unit stay. 
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6.8 DATA COLLECTION: 
The hospital notes of all patients admitted to the Asthma 
Unit were reviewed upon their discharge. The time taken to 
achieve maximum PEFR in hours was calculated from the time 
of arrival in the emergency unit to the maximum PEFR 
recorded on the peak flow chart. 
As the exact time of discharge is relatively arbitrary and 
difficult to determine, each day was divided into 6-hour 
time units (OOh00-06hOO, 06h00-12hOO, 12h00-18hOO, 18h00-
24h00). The duration of stay was then calculated in time 
units from the time unit of arrival in the emergency unit to 
that of discharge. A note was made of the need for 
salbutamol infusion and the need for Intensive Care Unit or 
medical ward admission. The prior use, if any, of oral 
maintenance steroids was recorded. 
6.9 INCLUSION CRITERIA: 
Patients were required to show evidence of reversibility of 
airflow obstruction with an initial increase in PEFR >20% 
(over the value on presentation) after the first salbutamol 
nebulisation had been administered, or an overall increase 
in PEFR >100% at any time during the admission. 
In addition, patients were required to meet strict criteria 
for the severity of asthma, namely that the initial PEFR was 
less than 50% of the predicted value. Predicted PEFR was 
calculated according to Cote's formula41
 as follows: 
Females: (Height(metres) x 6.23 - 0.035 x Age - 1.88] x 60 
Males: (Height(metres) x (6.58 - 0.025 x Age)] x 60 
As indicated in paragraph 5. 4, these criteria will have 
selected the more obstructed patients. However as the main 
endpoints did not include a direct comparison of 
31 
bronchodilator response, this is unlikely to have affected 
outcome. In addition, the group studied is likely to have 
included some patients with chronic obstructive lung disease 
with a "reversible element" to the airflow limitation. 
6.10 EXCLUSION CRITERIA: 
Patients with evidence of other cardiorespiratory disease 
( eg. pneumonia, pneumothorax, pulmonary oedema or severe 
chronic obstructive lung disease) were excluded from further 
analysis. Those patients whose therapy deviated from the 
basic protocol were analysed separately, as were those who 
were transferred to a medical ward or intensive care unit. 
6.11 ACUTE SEVERE ASTHMATICS NOT INCLUDED IN THE STUDY: 
In order to determine how representative the study group was 
of the overall hospital asthmatic population, the records of 
all patients with acute severe asthma admitted elsewhere in 
the hospital during the study period were examined. Cases 
were identified by scrutinising the emergency unit patient 
registers and identifying admissions in whom a diagnosis of 
asthma was recorded or a nebulised B2-stimulant was 
administered. 
6.12 ETHICAL APPROVAL AND CONSENT: 
Patients were inf armed that a study was being conducted 
using two forms of corticosteroid treatment of similar 
effectiveness. Their verbal consent to participaton in the 
study was obtained. The study was approved by the 




The Chi-square, Student's t, Mann-Whitney U and Median tests 
were used when appropriate to determine the significance of 
findings when comparing the HC and MP groups, as well as the 
four subgroups: Hydrocortisone and maintenance steroid, 
methylprednisolone and maintenance steroid, hydrocortisone 
without maintenance steroid and methylprednisolone without 
maintenance steroid. 
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CHAPTER 7: RESULTS 
7.1 STUDY POPULATION AND EXCLUSIONS: 
386 patients were admitted to the Asthma Unit during the 
study period. The following categories were excluded from 
further analysis: i) 38 patients who had previously been 
diagnosed as suffering from chronic obstructive lung 
disease, non-asthmatics and patients who received oral 
theophylline therapy; ii) 58 patients who did not meet the 
study criteria for reversibility of airflow obstruction 
and/or the criteria for acute severe asthma; iii) 47 
patients who were not given intravenous corticosteroids of 
whom 18 were treated with oral corticosteroids; iv) 33 
patients who required the addition of a salbutamol infusion 
to the standard therapy; v) 19 patients who were transferred 
to the medical wards. 
Table 7.1 shows the comparative proportions of patients in 
the MP and HC groups that were treated with more intensive 
therapy in the form of intravenous salbutamol (in addition 
to the usual regimen) and also shows patients transferred to 
the medical wards. The indications for transfer to a 
general medical ward were: associated medical illnesses (4), 
asthma unit full (1), persistent bronchospasm or judged to 
be unstable ( 14) • No patients were transferred to the 
intensive care unit. 
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7.2 BASELINE COMPARISONS: 
Thus, after the exclusions detailed above, analysis was 
confined to 191 patients; 91 in the BC and 100 in the MP 
groups respectively. Analysis of baseline data showed the 
groups to be comparable. No significant differences were 
seen between the MP and BC groups in age, predicted PEFR or 
PEFR as "percentage of predicted" after the first nebuliser 
was administered. The relevant data is illustrated in Table 
7.2. Significantly more males were present in the MP group. 
Almost equal numbers of patients were on oral maintenance 
steroids at the time of admission. 
TABLE 7.1 


































































































































































































































































































































































































7.3 ENDPOINT ANALYSIS: 
7.3.1 TIME TO MAXIMUM PEFR: 
The median ti.me to maxi.mum PEFR was 19 hours for HC compared 
to 23 hours for MP. This trend favouring HC did not reach 
statistical significance (p=0.21). In view of the non-
Gaussian distribution of values (illustrated by the box 
plots in figure 2) the (non-parametric) Mann-Whitney test 
was used. The mean maximum PEFR (percentage of predicted) 
which was achieved did not differ in the two groups [HC 
81.5% (+20.3) vs MP 81% (±21.6); p=0.87 t test]. 
7.3.2 DURATION OF HOSPITAL STAY: 
The median asthma unit stay was 30 hours (5 six-hour time 
units) for HC compared to 36 hours for MP. This difference 
was statistically significant ( p=O.01, Median test) . The 
wide range in hospital stay as illustrated in figure 3 is 
accounted for by a few patients with prolonged admissions. 
The difference in hospital stay is illustrated more clearly 
by plotting duration of hospital stay as a "survival curve" 
as shown in figure 4. A difference is apparent within 12 
hours and continues beyond 36 hours. 
In order to compare the status of the small number of 
patients in the two steroid groups with a more prolonged 
hospital stay, the median PEFRs (% of predicted) were 
examined. After 24 hours, the HC and MP groups had achieved 
equivalent percentages of predicted PEFR. However, at 48 
hours after admission, the HC group had achieved a median of 
71. 8% of predicted PEFR, which differed significantly from 
the 56. 9% of the MP group (p=O. 009, Mann-Whitney U test). 
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PEFR ACHIEVED AFTER 24 AND 48 HOURS 
HC MP MANN-WHITNEY U 
24 HOURS 
n= 58 72 
%predicted PEFR 70.7 68 P=0.99 
[54.7/85.0] [56.6/86.9] 
48 HOURS 
n= 19 24 
%predicted PEFR 71. 8 56.9 P=0.009 
[57.4/81.9] [50.8/61.0] 
[] Denotes 25th and 75th centiles. 
7.4 SUBGROUP ANALYSIS: 
The HC and MP groups were subdivided according to prior oral 
maintenance steroid therapy. The comparison of the four 
resultant subgroups is shown in Table 7.4. The HC patients 
not on maintenance steroids were significantly younger than 
those who had been on maintenance steroids. Once again, a 
difference favouring HC is seen in the duration of hospital 
stay and this reached statistical significance in those who 
were on oral maintenance steroids before admission. No 









































































































































































































































































































































































































































































































































































































































































































































7.5 THEOPHYLLINE LEVELS: 
Theophylline level estimations were performed on serum 
samples drawn daily at 08h00. The results are reflected in 
Table 7.5. A large proportion of patients had 
subtherapeutic serum levels. This proportion did not vary 
appreciably over three days except in the HC group where a 
progressive rise in the percentages with toxic levels was 
seen. 
TABLE 7.5 
THEOPHYLLINE LEVEL ESTIMATIONS 
DAY 1 2 
HYDROCORTISONE 
Number tested 82 37 
Subtherapeutic ( % ) 42.7 48.6 
Therapeutic ( % ) 53.7 40.5 
Toxic ( % ) 3.7 10.8 
METHYLPREDNISOLONE 
Number tested 96 53 
Subtherapeutic ( % ) 39.6 39.6 
Therapeutic ( % ) 51 54.7 
Toxic ( % ) 9.4 5.7 
Theophylline level reference ranges: 
Subtherapeutic: <55 umol/1 
Therapeutic: 55-110 umol/1 











7.6 PATIENTS NOT INCLUDED IN STUDY: 
29 patients with a possible diagnosis of acute severe asthma 
were admitted elsewhere in the hospital during the study 
period. Review of individual case records showed that 10 of 
these had previously been diagnosed as having severe fixed 
airflow obsruction. Therefore 19 asthmatics admitted 
elsewhere in the hospital were not included in the study 
data. 
These cases were distributed as follows; 
A. Medical ward admissions (n=l2): 
i) 10 cases with asthma asssociated with other medical 
illnesses (pneumonia 7, pulmonary tuberculosis 1, 
pneumothorax 1, severe bronchitis 1) 
ii) 2 cases with acute severe asthma 
B. Intensive care unit admissions (n=7): 
Patients with acute severe asthma complicated by other 
medical illnesses are not considered suitable for Asthma 
Unit management. Six of the intensive care unit admissions 
required mechanical ventilation and intubation was performed 
shortly after arrival in the emergency unit. The two 
patients with acute severe asthma uncomplicated by other 
illnesses (who were admitted to the medical wards) were more 
severe asthmatics as they had both previously required 
mechanical ventilation and had carbon dioxide retention on 
admission arterial blood gas analysis. 
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CHAPTER 8: DISCUSSION 
8.1 INTRODUCTION: 
Difficulties inherent in the clinical study of the treatment 
of acute severe asthma have been discussed earlier. The 
effects of the heterogeneity of the asthmatic population 
with variable rates of recovery, severity of asthma, drugs 
used and their dosages cannot be overlooked. In view of the 
limitations in previously cited studies, a large number of 
cases was entered into this study in order to eliminate type 
2 error in relation to sample size. 
8.2 ENDPOINTS: 
The HC group appeared to achieve maximum PEFR values sooner 
than the MP group. A similar difference favouring HC is 
seen in the "HC with maintenance steroid" subgroup. Neither 
of these differences, however, proved to be statistically 
significant. 
From the literature reviewed earlier, it is clear that there 
is a delay in the onset of action of corticosteroids which 
amounts to several hours. In both groups there were 
patients who achieved maximum PEFRs shortly after admission. 
These early responders would probably improve on 
bronchodilators alone irrespective of steroid therapy. The 
use of non-parametric significance testing obviates the 
possibility of these patients concealing differences between 
the BC and MP groups. 
A significantly longer duration of hospital stay was seen in 
the MP treated patients. This was true of the steroid 
groups as a whole (MP n=lOO vs HC n=91) as well as in the 
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subgroup which had been on oral maintenance steroids prior 
to admission. 
Figure 4 clearly illustrates the comparison of hospital stay 
in the HC and MP groups. In the initial few hours there is 
no difference. Thereafter the numbers in the HC group 
decrease more rapidly until, beyond 48 hours there are small 
numbers in each group with no difference between the two. 
Further analysis of these "long stayers" would be 
inappropriate as it is from amongst these patients that the 
group transferred to the medical ward was drawn. Of the 19 
patients transferred to a medical ward, 52. 6% were in the 
Asthma Unit for 48 hours or longer prior to transfer. 
The study exclusion criteria would have had a significant 
effect on this subgroup, which is likely to have included 
severe asthmatics, patients with chronic obstructive lung 
disease and possibly so-called steroid resistant 
asthmatics. 37 
The validity of the difference in the duration of hospital 
stay is supported by the additional observation that, in 
those remaining in the Asthma Unit after 4 8 hours, the MP 
group had achieved a lower percentage of predicted PEFR. 
The consistency of the pattern favouring HC in both major 
endpoints of the study lends further support to the validity 
of the findings. 
This consistent pattern remains when the entire sample 
population is examined, although with decreased significance 
levels on statistical analysis. Appendix 2 reflects the 
results obtained when examining the sample population as a 
whole, excluding only non-asthmatics and ward transfers 
(i.e. irrespective of the need for salbutamol infusion and 
the criteria for obstruction and reversibility). 
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8.3 ISSUES ARISING FROM THE CONDUCT OF THE STUDY: 
The choice of study design (including randomisation) ensured 
that the study was performed by the Asthma Unit staff in the 
normal course of their duties with a minimum of departures 
from their usual treatment schedules. The survey was 
conducted in the emergency unit with a staff of 18 full-time 
and about 12 sessional doctors. Individual doctor bias with 
regard to admission or discharge is the ref ore unlikely to 
have systematically affected the study. The results 
obtained highlight the relative efficacy of hydrocortisone 
and methylprednisolone in a commonly encountered clinical 
situation. 
During the study period only 3 cases of acute severe asthma 
not complicated by other illnesses or requiring mechanical 
ventilation were admitted elsewhere in the hospital. The 
sampled population can therefore be regarded as being 
representative of the uncomplicated hospital asthmatic 
population. 
In view of the generally short duration of admission and 
inaccuracies in determining the exact moment of discharge, 
the use of 6-hour time units was useful and more appropriate 
than timing an admission in terms of days or hours. The 
difference in median duration of admission was only one time 
unit. This does not necessarily indicate a difference of 6 
hours and may conceal a smaller or larger difference. An 
analagous situation is seen with the PEFR monitoring. For 
obvious reasons this cannot be measured continuously but is 
done at intervals (in this case 4-hourly). Time to maximum 
PEFR could equally therefore be viewed as comprising 4-hour 
time units. 
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8.4 ISSUES ARISING FROM THE STUDY RESULTS: 
The HC and MP groups are well matched in terms of age, 
baseline status and previous maintenance steroid therapy. 
The difference in gender distribution is unlikely to have 
had any bearing on outcome. In particular, one should note 
the absence of any difference between the steroid groups 
with respect to the number of patients excluded from 
analysis because of ward transfers or need for a salbutamol 
infusion. The absence of any intensive care unit transfers 
indicates that, on the whole, the emergency unit staff 
correctly reserved the Asthma unit for patients who were not 
critically ill. 
The cases studied here all met strict criteria for severe 
asthma and reversibility of airflow obstruction and were not 
complicated by other acute illnesses. Therapy in hospital 
was carefully standardised with nebulised B2-stimulants and 
aminophylline infusions. There was no control of, nor was 
any attempt made at adjustment for other factors, such as 
precipitants of the acute severe asthma, duration of the 
acute attack at the time of admission or therapy received 
prior to arrival at the hospital. The absence of attempts 
to "control" for the above features in any given patients 
was, again, consistent with the practical demands of a busy 
Asthma Unit service; at the time of admitting patients in 
the acute phase of an attack, doctors are rarely able to 
predict the likely subsequent course with confidence. 
A large proportion of patients had sub-therapeutic 
theophylline levels although this did not differ appreciably 
between the two steroid groups. It is unlikely that this 
factor resulted in any difference in outcome between the HC 
and MP groups. The theophylline levels shown in this study 
are a reflection of inadequate therapeutic drug monitoring 
in the Asthma Unit due to cost constraints. Instead, an 
elaborate method for calculating the dose for each patient 
is used ( see Appendix 1). Monitoring over the past few 
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years has consistently shown that application of the formula 
results in 50% therapeutic levels, 10% toxic levels and the 
remainder subtherapeutic - a pragmatically acceptable mix 
(5 J Lauw, personal communication July 1993). 
8.5 OTHER CONSIDERATIONS: 
One might speculate why, despite the advantages of MP 
discussed earlier, this steroid performed less well than HC 
in the clinical situation. The optimal dosage interval is 
not known for the longer acting steroids and the 12-hourly 
dosing schedule may have been too wide. However the 
administration of MP at intervals approximately equal to 
half the biologic half-life would generally be regarded as 
appropriate. Secondly there is a possibility that the 
frequent peaks in plasma cortisol achieved with 4-hourly HC 
administration may have some added effect in certain 
asthmatics. This question is particularly relevant in the 
light of the experimental work by Boudinot and others 
referred to in paragraph 3.2. If their findings are valid, 
the 4-hourly dose scheduling of HC would have placed it at 
an advantage over MP. Finally it is possible, although 
unlikely, that the inadvertent omission of a dose of a drug 
might have a significant effect especially if doses are 
widely spaced. 
In recent years the need for intravenous as opposed to oral 
steroids has been questioned. Jonsson et a142
 reported that 
the oral administration of steroids was as effective as 
intravenous use in 









was no advantage to the 
addition of parenteral to high dose oral steroids in the 
study by Harrison et al 43 of patients with severe asthma 
(PEFR <30% predicted) without ventilatory failure. More 
recently, Ratto et al44 compared oral and intravenous MP and 
again could show no difference in improvement in FEV1, 
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duration of hospitalisation and rate of improvement in 
pulmonary function. These patients had mean admission FEV1 
( % predicted) of 26-27% ( and were therefore of comparable 
severity to those reported here) but had a mean 
hospitalisation of more than three days. The degree of 
reversal of airflow obstruction after 24 hours of treatment 
was equivalent to that obtained in this study. 
These studies by Jonsson, Harrison and Ratto were analysed 
in Rowe's meta-analysis36 and the results showed that the 
effect on pulmonary function of oral and intravenous 
steroids were equivalent. The marked cost saving with oral 
steroids makes their use an attractive option. 
8.6 RELATIVE COST-EFFECTIVENESS: 
Although HC appears to be more effective in this study, this 
is not equivalent to superior cost-effectiveness. No 
previous studies have presented a practical model for drug-
drug cost-effectiveness evaluations in acute asthma. The 
proposed model for drug cost-effectiveness analysis by 
Gagnon and Osterhaus45 requires the determination of an 
effectiveness ratio for each drug. This was done by 
multiplying the "probability of healing" (with the use of 
each drug) by the "proportion not affected by a clinically 
important (adverse) condition." An effectiveness to cost 
ratio was then obtained by 
effectiveness ratio by its cost. 
dividing each drug's 
The data obtained in this 
study does not lend itself to this type of calculation. 
The actual cost to the hospital for these corticosteroids at 
the time of the study was HC(l200mg) R32.52 and MP(250mg) 
Rl 7. 78. 46 The cost, in terms of corticosteroid alone, of 
treating a patient with HC for the median admission period 
of 30 hours would amount to R37. 94. In the case of MP 
(median admission 36 hours) the cost comes to R26.37. 
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In addition to the cost advantage of using MP in terms of 
drug costs alone, other factors need to be considered. In 
evaluating cost-effectiveness, the daily cost of a 
theoretical "hospital bed," consumables (needles, swabs, 
syringes, etc) and duration of admission should be included. 
If MP is administered 12-hourly, it results in a 2/3 
reduction in consumable expenditure and nursing time as 
compared to 4-hourly BC. For this reason MP is strongly 
favoured over BC by nursing staff in the Asthma Unit. 
Nevertheless the costs of intravenous corticosteroids do 
vary from time to time and the clinician needs to regularly 
review the relative cost advantages in the light of relative 
drug efficacy. As an example, the current (1993) costs of 
intravenous steroids at Groote Schuur Hospital are: HC (1200 
mg) R28.76 vs MP (250mg) R45.54. 
The administration of corticosteroids as a continuous 
infusion would eliminate differences in consumable and 
labour costs. The relative efficacy of intravenous 
continuous and bolus dose corticosteroid therapy is not 
known. 
8.7 CONCLUSIONS: 
In conclusion, this study has shown an increased duration 
of hospital stay in patients with acute severe asthma 
treated with intravenous MP compared to those treated with 
HC. These differences, al though small, are both 
statistically significant and consistent, but may for 
practical reasons have little bearing on the clinical choice 
of corticosteroid. There are indications that more severe 
asthmatics (as evidenced by their need for oral maintenance 
steroids) do better on HC. In general the decision to use 
HC or MP may be based on financial and labour-effectiveness 
considerations. 
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The simple and inexpensive study design used here has 
answered a relevant clinical question. This form of 
interventional survey can be used or adapted further for the 
evaluation of drug therapy and other management options, 
particularly in a setting such as the Asthma Unit. This 
could be a powerful clinical tool if used carefully and 
selectively. It could be particularly relevant in Africa 
where specific answers to local problems under local 
conditions are required and where classic experimental 
studies would place unrealistic demands on finances and 
personnel. 
8.8 RECOMMENDATIONS: 
In general, there is little difference between the efficacy 
of BC and MP in acute severe asthma. In the most severe 
acute attacks (eg in intensive care) the small advantage of 
HC may be more relevant. The fact that a difference between 
two high-dose steroid regimens could be shown in the present 
study raises serious questions regarding the current 
tendency to introduce lower dose and oral steroid regimens. 
The effectiveness of these reg.1.mens should be demonstrated 
under local conditions prior to their implementation. 
1 
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APPENDIX 1 
ASTHMA UNIT OPERATING PROTOCOL 
NOTES FOR MEDICAL OFFICERS IN THE EMERGENCY UNIT 
A. INTRODUCTION: 
Acute severe asthma is a potentially fatal condition. It 
has been shown that a frequent cause of death is under-
treatment, 
doctor. 
due to inadequate 
Often the doctor 
assessment by the 
and patient both 
attending 
fail to 
appreciate the severity of the attack; objective tests such 
as the Peak Flow Rate, pulsus paradoxus and blood gases are 
therefore mandatory in the proper management of severe 
asthma attacks. 
The "Asthma Room" is unique in this hospital in several 
respects: 
(a) it is the only ward to which patients are admitted with 
a life-threatening illnesss without undergoing full 
clerking by a registrar and an intern; 
( b) it has a very high turnover; 
( C) many patients are re-admitted several times a year and 
staff get to know them; 
( d) patients sit fully clothed in chairs. 
These four factors all tend to militate against proper 
assessment and care of these severely ill patients. We 
therefore have a strictly disciplined monitoring procedure 
and our treatment schedules have been standardized to avoid 
confusion. If you ignore our procedures and schedules, you 
cannot expect the safety net to work - and I shall have 
difficulty in defending you in court. 
Despite its obvious deficiencies, the Asthma Unit provides 
an essential sevice in Groote Schuur Hospital, by relieving 
the pressure on Medical Ward beds and making maximum use of 
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dedicated nursing staff. Some of the nurses in the Asthma 
Unit have been looking after asthmatics for years and they 
have a clear understanding of the value and limits of our 
monitoring procedures, our drug schedules and our criteria 
for referral and discharge. You ignore their suggestions at 
the patients' peril. New doctors often find their first day 
in the Asthma Unit a "harrowing" experience; but as they 
come to grips with our schedules and procedures, they 
invariably realise that these are not designed to create 
work but to reduce it, yet ensuring the maximum safety of 
the patient. 
It is therefore imperative that you study these guidelines 
carefully. (You might as well learn how the system works by 
this easy way rather than through trial and error •.• ) 
B. DUTIES OF MEDICAL OFFICERS WITH RESPECT TO ASTHMA ROOM: 
(a) Ante-Room Staff. 
(i) New admissions are primarily seen by the ante-room 
staff unless the Asthma Unit medical officer is free. 
Severely ill asthmatics should be kept under 
observation in the Ante-room whilst blood gases and 
electrolytes are being done and the decision to refer 
to the Respiratory Intensive Care Unit is in the 
balance. 
Patients who complain of chest pain should have a chest 
x-ray (to exclude pneumothorax or pneumonia) and an ECG 
if appropriate. Where a cough produces mucopurulent 
sputum a specimen should always be sent for microscopy, 
culture and sensitvity, Ziehl-Nielsson stain and fungal 
culture. Blood glucose should be checked where 
appropriate. If there is any question of theophylline 
toxicity being present, a blood specimen must be taken 
without delay. 
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(ii) Ante-room staff should retrieve the "Baseline Data 
Sheet" ( if one exists) and complete an "Urgent 
Admission Data" form. Please tick the relevant boxes 
and do not use unconventional symbols. A new "Urgent 
Admission Data" form should be completed on every new 
admission. 
(iii) The admitting medical officer should write up the 
treatment charts, including fluid balance chart and 
oxygen therapy. 
(iv) The patient remains the responsibility of the 
clerking medical officer until he or she has done a 
formal hand-over to another medical officer (usually 
the Asthma Unit medical officer) in the presence of the 
patient. 
(v) The Asthma Unit is designed for the care of 
straightforward severe asthmatics. Complicated cases, 
eg. with cardiac failure, metabolic disturbances, 
pneumonia or confusional states should not be admitted 
to the Asthma Unit. Equally end-stage Chronic 
Obstructive Lung Disease patients should not be 
admitted to the Asthma Unit, since they usually require 
a long hospital stay and deplete the Asthma Unit' s 
resources. 
(b) Asthma Unit Medical Officer 
(i) Early morning ward round. 
Read through the patients' records and complete 
"Baseline Data" forms for all patients that do not 
already have these. Note that patients need to be 
examined on a couch or bed, ideally. Note also that we 
use the American Thoracic Society criteria for the 
classification of dyspnoea. Update existing "Baseline 
Data" sheets. 
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Assess each patient from the point of view of response 
to therapy and complications of therapy. Perform 
appropriate blood tests. Personally check inhaler 
technique in all patients. Identify patients who do 
not know how to use their inhalers, new asthmatics and 
patients who seem to lack an understanding of their 
condition - for instruction by yourself later on, with 
the assistance of available nursing staff. 
Arrange for Chest x-rays on patients who have not had 
one for more than one year, all new patients, patients 
who fail to show a response to 24 hours of therapy, 
patients with chest pain, patients with haemoptysis or 
pyrexia. 
Decide which cases you would like to discuss on Dr. 
Louw' s round. 
rays ready. 
Get their Baseline sheets and chest x-
(ii) Late morning round. 
Write up discharge medicines and discharge letters. Ask 
nursing staff to make appointments for follow-up. See 
unstable cases. Discuss difficult cases with Dr. Louw. 
See results of investigations. 
(iii) Afternoon round. 
Get results of the electrolytes and theophylline levels 
requested that morning and make appropriate alterations 
to therapy. See all cases again. Check peak flow 
technique in cases that seem resistant to therapy. 
Check medication charts. Educate patients about their 
condition and use of inhalers. Discuss unstable or 
deteriorating cases with hand-over medical officer in 
ante-room in the presence of the relevant patients. 
(iv) Investigations: 
All patients should have a 6/60 and chest x-ray on the 
second morning of their stay in the Asthma Unit, i.e. 
60 
24-40 hours after admission, (unless they are due for 




(a) All patients receive Berotec by nebuliser, 1:4 ml 
saline, 4 hourly; in more distressed patients this can 
be given 2-hourly. 
(b) Distressed asthmatics should be given oxygen by face 
mask (40%) when they are not using the nebuliser. 
( c) Aminophy lline: This drug should be used with extreme 
caution in patients: 
(i) who have been using theophylline containing 
preparations prior to presentation; 
(ii) with impairment of liver function; 
(iii) with heart failure, since toxicity frequently 
develops. The ad.ministration regimen is described at 
the end of these notes. 
(d) Intravenous salbutamol should be used in the following 
cases: 
(i) Where aminophylline is contra-indicated; 
(ii)Patients who appear not to have responded to 
aminophylline infusion after 6 hours (this might be due 
to the fact that therapeutic aminophylline levels have 
not been achieved, but no scientific basis for 
increasing the dose without knowing the theophylline 
level exists), or the patient appears to be resistant 
to aminophylline. 
NOTE: That hypokalaemia often occurs in patients on 
high dose salbutamol. The electrolytes should be 
checked daily and supplemental potassium given as 
necessary. 
(e) Methylprednisolone should be used in the following 
cases: 
( i) All patients who required prednisone ( or other 
corticosteroid) treatment in the preceding three months 
as part of their maintenance therapy. 
(ii) All patients who have been in the Asthma Unit 
during the preceding four weeks. 
(iii) All patients who fail to show a satisfactory 
response to the treatment outlined above within the 
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first ONE hour after admission. "Satisfactory 
response" may be defined as improvement with regard to 
general state of distress, reduction of tachycardia and 
pulsus paradoxus and improvement of PEFR by 50% or 
more. (e.g. PEFR on admisson = 60 going up to 90, or 
90 on admission going up to 135 would constitute a 
satisfactory response in the first hour). 
(iv) Patients who, on previous admissions to the Asthma 
Unit, showed a slow recovery curve and/or required IV 
methylprednisolone. 
(f) Ipratropium Hydrobromide may be administered by 
nebuliser in cases that are particularly resistant to 
therapy or those who have significant adrenergic side 
effects. 
( g) Antibiotics should be used in patients who produce 
yellow sputum. Always send a specimen to Bacteriology 
for microscopy, culture, sensitivity and fungal 
culture. 
(h) Occasionally, dehydration may be responsible for a 
patients failure to improve. Features such as a dry 
tongue and reduced skin turgor should be noted. 
(i) Pregnant asthmatics: 
Available data indicate that the hypoxaemia caused by 
acute asthma leads to foetal wastage. All pregnant 
asthmatics in the Asthma Unit should receive continuous 
oxygen by nasal cannula. Treatment of these patients 
with steroids and bronchodilators should be along 
standard lines; there is no contra-indication to any 
of the drugs in acute asthma. 
Upon discharge, all pregnant asthmatics should be given 
a fallow-up appointment at the Allergy Clinic within 
one month. 
(j) Bronchiectasis: 
Patients with bronchiectasis who come to hospital with 
flare-ups should be admitted to a ward, since the 
mainstay of their therapy is antibiotics, postural 
drainage and education. These patients should not be 
admitted to the Asthma Unit. 
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(k) Allergic Bronchopulmonary Aspergillosis: (ABPA) 
This condition is present in a significant proportion 
of severe asthmatics. It is due to a hypersensitivity 
reaction to the fungi that colonize the airways. 
Remember that a patch of pneumonia and upper lobe 
fibrosis may be due to this condition. Look for fungi 
in the sputum and send blood to bacteriology for 
aspergillus precipitins in suspected cases. Such cases 
should be seen in the Allergy Clinic for follow-up. 
( 1) Patients with chronic obstructive lung disease should 
only be admitted to the Asthma Unit if the Asthma Unit 
is relatively empty. Remember that inappropriate 
admissions put a strain on the nursing staff and reduce 
the amount of attention they can give the true 
asthmatics. COAD patients should be treated with 
bronchodilators and steroids and discharged when their 
effort tolerance has returned to their usual effort 
tolerance. COAD cases that come to the hospital 
frequently should be referred to the Respiratory Clinic 
for follow-up. 
If the Asthma Unit is more than 50% full, no further 
COAD cases should be admitted - these patients should 
be admitted to the wards. The successful running of 
the Asthma Unit depends very much on Ante-room staff 
observing this rule. 
D. MONITORING OF RESPONSE: 
The doctor's failure to recogninse the severity of an attack 
is known to be a major cause of fatality in acute severe 
asthma. The premonition of death in a patient is often a 
significant prognostic symptom. A patient with explosive 
onset of bronchospasm calls for early, aggresssive 
intervention and extremely close monitoring. 
In monitoring patients look at:-
(a) peak expiratory flow rate (PEFR) - severe if <90; 
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(b) width of pulsus paradoxus - severe if >20; 
(c) pulse rate (less useful when drugs are being given) -
severe if >130; 
(d) pulse volume - a thready pulse is ominous - and signs 
of poor peripheral perfusion; 
(e) general state of patient; 
(i) ability to breath-hold or speak; 
(ii) degree of distress as evidenced by the use of 
accessory muscles; 
(iii)evidence of confusion or 
(iv) exhaustion; 
(f) cyanosis; 
(g) character of respiration and onset of a "quiet chest". 
Arterial blood gases should be done repeatedly in all cases 
that are: 
(a) still judged to be severe after 
bronchodilator therapy; 
(b) showing any evidence of deterioration; 
(c) showing evidence of onset of exhaustion; 
(d) thought to be cyanosed at any stage. 
1/2 hour 
E. REFERRAL TO RESPIRATORY ICU AND EMERGENCY INTUBATION; 
of 
(a) Refer the following categories of patient for admission 
to the Respiratory ICU: 
(i) Patients that become progressively more exhausted; 
(ii) Patients that fail to respond to therapy and show 
a progressive rise in their PaC02; 
(iii)Onset of metabolic acidosis and/or circulatory 
shutdown; 
(iv) Confused and uncooperative patients judged to be 
in severe status asthmaticus should be referred 
urgently. 
(b) If there is delay before the Respiratory registrar can 
see the patient and if it appears that the patient is 
deteriorating further despite IV therapy, nebulizer 
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therapy and 40% oxygen by face mask, then an awake 
intubation should be performed after spraying the 
larynx with local anaesthetic. 
F. REFERRAL TO MEDICAL WARD 
(a) Patients with acute severe asthma with marked metabolic 
disturbances, such as diabetes or renal failure. 
(b) Patients who fail to show a satisfactory improvement 
after 48 hours in the Asthma Unit, should be considered 
for admission; after 4 days the patient should 
definitely be admitted. 
(c) Patients fulfilling the criteria under "E" above, when 
the respiratory intensive care is full. 
G. ASTHMA DEATHS: RISK FACTORS 
The fallowing are features that have been recognised in 
association with asthma deaths. 
(a) Incomplete asssessment of the severity of asthma and 
insufficient treatment; 
(b) Morning dipping - death usually occurs in the early 
hours of the morning; 
(c) Prolonged severe attacks of asthma; 
(d) Frequent attacks of acute severe asthma; 
(e) Large diurnal variations, i.e. pronounced early morning 
dipping; 
(f) Progressive deterioration over months; 
(g) Inadeqate use of corticosteroids to prevent attacks. 
Factors c,d,e and f are generally problems that cannot be 
solved within two or three days in the Asthma Unit - such 
patients should therefore be admitted to a medical ward for 
stabilisation. 
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B. DISCHARGING PATIENTS: 
1. INTRODUCTION: 
Ideally an asthmatic should be kept under observation 
following the resolution of an acute severe attack until 
he/she has achieved a plateau corresponding to his/her best 
achievable PEFR and until "morning dipping" has been 
controlled. In our unit the pressure of numbers does not 
permit us to practice ideal medicine, so we have to make a 
compromise. In the running of the Asthma Unit there should 
always be an awareness of the balance between the number of 
chairs available for future admissions and the severity of 
the incumbents. When the Asthma Unit is relatively empty, 
one can afford to keep the more severe cases in for longer 
than is usually our practice. 
2. ELIGIBILITY FOR DISCHARGE: 
Patients may be deemed eligible for discharge if they 
satisfy all the following criteria:-
( i) No features of respiratory distress and able to 
walk to the toilet. 
(ii) PEFR shows an upward trend or has plateaued at 
more than 70% of patient's best PEFR in the past year 
(or, if not available, predicted normal PEFR) and 
morning dipping is not below 50% of the patient's best 
PEFR in the past year (or predicted normal PEFR). 
(iii) Patient feels that he/she would be able to cope 
at home. 
3. THE DISCHARGE PRESCRIPTION: 
Factors to be considered: 
Al though the format of this prescription would be similar 
for many of our patients, it should never be regarded as 
"standard". When you are writing the prescription and 
planning follow-up, the following questions should be 
considered:-
(a) How poor has the control, in general, of this patient's 
asthma been over the past year? Consider: Number of 
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times the patient required Asthma Unit therapy or IVI 
therapy elsewhere; number of days work missed; 
nocturnal waking; general effort tolerance. 
Poor control might have been due to:-
(i) the patient's ignorance and consequent non-
compliance (remedy: educate patient and arrange closer 
follow-up by the Day Hospital); 
(ii) chronically under-treated asthma (remedy; look at 
the patient's maintenance therapy and decide at which 
step in the cascade (see below] he/she should really be 
maitained; write a clear letter to the Day Hospital in 
which you clearly state your recommendations); 
(iii) the tailing-down-steroids-rebound syndrome: we 
have a substantial population of asthmatics with this 
syndrome, who regularly develop acute severe asthma 
whenever their prednisone falls below a certain 
threshold; they are often patients who require 
admission every 3 - 6 weeks (remedy: do not tail down 
their prednisone dose too rapidly and do not go below 
the critical threshold, often about 10-15 mg/day; 
(iv) truly labile and truly resistant cases: when the 
abovementioned factors leading to poor control of 
asthma have been excluded, a few patients will be found 
to fall into this group (remedy: refer to Respiratory 
clinic for follow-up). 
(b) Are there clearly definable factors that precipitate 
the attacks? Consider: atopic status, drugs that cause 
asthma, pets, hobbies, occupation and reactions to food 
and food additives. Clearly, advice regarding the 
avoidance of precipitating factors, where appropriate, 
is more valuable than thousands of rands of drugs. 
( c) What is the nature of the present attack? If the 
present attack was of explosive onset and life-
threatening severity, a very diligent search for the 
precipitating cause should be made. If none is found 
consideration should be given to supply the patient 
with a home nebuliser or with adrenaline for 
subcutaneous injection. 
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DRUGS TO BE USED: 
(a) Principal drugs. 
Almost all the patients will require all of the 
following drugs: 
(i) Inhaled beclomathasone. 
There has been an increasing awareness of the role 
that inflammation of the airways plays in patients 
with chronic, unstable asthma. Patients should be 
encouraged to use Beclomethasone inhalers 
regularly, even when they are feeling well. The 
usual dose is 2 puffs four times daily. In 
patients with a poor inhaler technique, Becotide 
rotahaler with rotacaps may be prescribed. 
(ii) A B2 adrenoreceptor stimulant inhaler: 
Ventolin, Berotec, Ipradol. Note that Ventolin is 
less expensive to the hospital than other 
preparations and probably has similar efficacy. 
Unstable patients should take 2 puffs 3 to 4 times 
a day regularly, but can take up to 16 puffs a day 
if necessary. Ensure that the patients' technique 
in using the inhaler is satisfactory. If 
incoordination cannot be remedied, prescribe 
Ventolin rotacaps. 
(iii) Xanthines: Slow-release theophylline 
preparations: Nuelin SA, Euphyllin Retard or 
Theodur. Note that Nuelin SA is least expensive. 
If the dosage of these preparations is correctly 
adjusted, the need for Solphyllin falls away. 
(iv) Prednisone/prednisolone: The majority of our 
patients are steroid dependent asthmatics who 
require a short booster course of prednisone 
before it is tailed down to their maintenance 







the present attack of asthma 
wheezing before admission and 
three days in the Asthma Unit= 7 days; therefore 
(b) 
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prescribe prednisone 30 mg daily for 7 days before 
decreasing the dose) . The rate of reduction in 
the dose should be tailored according to the 
!ability of the patient's asthma and should also 
be slower in young asthmatics. It is safer to err 
on the side of a more prolonged course of 
steroids. Patients who are, in general, well 
controlled may require the following sort of 
regimen: 
Prednisone 30 mg daily for 3 days 
then 20 mg daily for 3 days 
then 15 mg daily for 3 days 
then 10 mg daily for 3 days 
then 5 mg daily for 3 days 
It is important to inform patients that, should 
their asthma deteriorate whilst they are tailing 
off their prednisone they should go back to the 
previous level of treatment and see a doctor the 
next day if their symptoms persist. 
Patients who are, in general poorly controlled, 
may need to remain at each level in the regimen 
for a week or longer. Very poorly controlled 
asthmatics should be discharged on prednisone30 mg 
daily for two weeks, then 25 mg daily for two 
weeks and should have a follow-up appointment 
within three weeks of discharge. 
Additional options. 
(i) Long-acting Salbutamol: 
If the patient's symptoms 
satisfactorily controlled in 
nocturnal cough and wheezing is 
problem, then adding Volmax 8mg 
adequate to control this symptom. 
appear to be 
general, but 
a persistent 
nocte is often 
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4. SOCIAL AND EMOTIONAL FACTORS: 
In some patients the stress produced by social or domestic 
pressures is such that it acts as a powerful precipitating 
factor of acute attacks. It is important to identify these 
cases and to intervene with the help of a social worker. 
Anxiety-induced acute severe asthma is no less severe than 
attacks precipitated by other factors and is recognised to 
carry a high mortality rate - probably because doctors are 
blinded by their concepts of pathogenesis. 
5. THE DISCHARGE LETTER: 
Every patient that is discharged from the Asthma unit should 
be given a letter to the doctor who normally looks after 
that patient. The patient should be clearly instructed to 
see his /her doctor within three weeks ( or sooner, where 
appropriate). The letter should contain information 
regarding your assessment of the general control of symptoms 
and your recommendation regarding future long-term 
maintenance steroid preparations. For convenience, two 
standard discharge letter formats are available in the 
Asthma Unit. The first, headed "Recent Attack of Acute 
Severe Asthma" merely informs the patient's usual doctor of 
his/her admission and discharge prescription. The second, 
headed "Frequent Attacks of Acute Severe Asthma" informs the 
doctor of the recent attack, discharge prescription and 
draws attention to the fact that the patient's condition is 
generally unstable. Please ensure that the correct 
discharge letter format is used in each case. 
6. FOLLOW-UP: 
The following patients should be given appointments in the 
Allergy Clinic: 
a. Patients with 3 or more acute severe attacks in 
the past 12 months. 
b. Pregnant asthmatics. 
c. Suspected cases of ABPA. 
d. Suspected occupational asthma. 
The following patients should be 




a. Patients with suspected interstitial lung disease. 
b. Asthmatics with a component of COAD, pulmonary 
fibrosis or cardiac failure. 
Thus the Allergy Clinic is best geared to see pure 
asthmatics, whereas the Repiratory Clinic is best geared to 
see asthma accompanied by other lung disorders. 
Other patients should be given a discharge letter with clear 
instructions to take their medications regularly and to go 
to their Day Hospital or general practitioner before they 
run out of medications. 
I. DRUG ADMINISTRATION REGIMENS 
1. INTRAVENOUS AMINOPHYLLINE: 
A.LOADING DOSE REGIMEN: 
Give 6mg/kg (ideal body mass) over 45 min. to patients 
who have not taken any theophylline containing 
preparations during the past 24 hours. If a history of 
some theophylline ingestion at home is obtained, but 
this is judged to have been inadequate to obtain 
therapeutic blood levels, then half the above loading 
dose may be given. If in doubt, go straight to the 
maintenance dose described below. 
B. MAINTENANCE DOSAGE: 
To be given as a 6-hourly infusion according to the 
patient's lean body mass and adjusted after 12 hours. 
Since the rate of excretion is slower in patients who 
do not smoke, are elderly, have liver or cardiac 
failure, different infusion rates apply to each 
category of patient 
1. Young adult smokers (<60 years old): Maintenance 
1.18 mg/kg/hr for 12 hours (i.e. 2 doses) then 
0.94 mg/kg/hr. 
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2. Young adult non-smokers (<60 years old): 
Maintenance 0.82 mg/kg/hr for 12 hours then 0.59 
mg/kg/hr. 
3. Elderly patients (>60 years) or patients with cor 
pulmonale: Maintenance 0.71 mg/kg/hr for 12 hours 
then 0.35 mg/kg/hr. Note that in patients with 
Cor pulmonale care should be taken not to 
overhydrate patients. 
4. Patients with cardiac failure/liver disease: 
Maintenance 0.59 mg/kg/hr for 12 hours then 
0.18mg/kg/hr. Note that in patients with heart 
failure care should be taken not to overhydrate 
the patient and a double strength infusion over 12 
hours might be preferable. 
2. INTRAVENOUS SALBUTAMOL: 
Put 10 mg salbutamol in 1 litre saline. 
Loading dose: 0.285 micrograms/kg/min over 15 minutes. 
Maintenance dose: 5 micrograms/minute. 
The principal side-effect or toxic effect of salbutamol is 
sinus tachycardia Beta adenoreceptor agents cause 
hypokalaemia which may be severe; thus patients on a 
salbutamol infusion should have their electrolytes checked 
daily. 
3. INTRAVENOUS CORTICOSTEROIDS: 
All patients are given 
intravenously every 12 hours. 






The data shown here reflects comparisons after excluding 
only the following categories: 
1. Patients with known chronic obstructive lung 
disease, non-asthmatics and patients who received oral 
theophylline (n=38) 
2. Patients not given intravenous steroids (n=47) 
3. Patients transferred to the medical wards (n=l9). 
Therefore the patients shown here are compared irrespective 
of their need for additional therapy ( salbutamol infusion) 
and without the application of criteria for the severity or 
reversibility of airflow limitation. Table 1 reflects the 
baseline demographic data and the comparison of outcomes is 
shown in Table 2. The only statistically significant 
comparison is that of HC vs MP in those who remained in the 
Asthma Unit after 48 hours. The consistent pattern showing 
a small superiority of HC over MP continues to be seen in 
the comparison of the duration of hospital stay and the time 
taken to achieve maximum PEFR. 
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